PTK2 and pancreatic ductal adenocarcinoma: GSK2256098 inhibited FAK Y397 phosphorylation and then suppressed FAK-related Akt/ERK activation, which led to the decrease of cell viability, anchorage-independent growth, and motility in a dose-dependent manner in pancreatic ductal adenocarcinoma cells [40].